About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Illinois | 664 Studies

Clinical Trials LymphomaIllinois

Lymphoma Clinical Trials in Illinois

Find 664 clinical trials for lymphoma near Illinois. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Illinois

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 361-380 of 664 trials

CompletedDose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P MutationRecent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B…NCT02252146·Los Angeles, California and 11 others TerminatedA Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell LymphomaTo evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.NCT00474188·Glendale, Arizona and 23 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedA Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell LymphomaThis is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous…NCT00476554·Stanford, California and 2 others

RecruitingA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's…NCT06911502·Birmingham, Alabama and 159 others

CompletedBiological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With CancerRATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.NCT00003408·Zion, Illinois

CompletedCombination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00003217·Little Rock, Arkansas and 13 others

CompletedStudy of the Safety and Tolerability of PCI-24781 in Patients With LymphomaThe first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma.NCT00724984·San Francisco, California and 7 others

Active not recruitingA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaB-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).NCT06508658·Duarte, California and 175 others

CompletedCombination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00006747·Birmingham, Alabama and 47 others

CompletedSafety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® TherapyThis study was to evaluate the safety and efficacy of a daily, oral dose of 10 mg RAD001 in participants with Mantle Cell Lymphoma who were refractory or intolerant to Velcade®…NCT00702052·Multiple Locations, Arizona and 30 others

TerminatedBrentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasThe purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of…NCT01805037·Chicago, Illinois and 2 others

RecruitingTesting the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaThis phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in…NCT04803201·Little Rock, Arkansas and 95 others

TerminatedA Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple MyelomaThis is an open-label, multicenter, 2-part study to determine the recommended Phase 2 dose (RP2D) for GSK2816126 given twice weekly by intravenous (IV) infusion.NCT02082977·Chicago, Illinois and 4 others

TerminatedRituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.NCT00335140·Stanford, California and 67 others

TerminatedStudy of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary SyndromeThe purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond…NCT00127881·Birmingham, Alabama and 34 others

Active not recruitingRadiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin LymphomaThis study focuses on using shortened courses of radiation for participants with relapsed/refractory Hodgkin/Non-Hodgkin lymphoma.NCT05019976·Chicago, Illinois

Active not recruitingStudy of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromPart A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small…NCT02952508·Los Angeles, California and 51 others

RecruitingA Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibThe master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies…NCT06876649·Jacksonville, Florida and 37 others

CompletedA Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL).NCT00500058·Chicago, Illinois and 1 other

TerminatedVaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.NCT00089115·Birmingham, Alabama and 59 others

PreviousPage 19 of 34Next

Other Conditions in Illinois

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia